Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

Anthem files lawsuit against Insys Therapeutics

A box of the Fentanyl-based drug Subsys, made by Insys Therapeutics Inc, is seen in an undated photograph provided by the U.S. Attorney's Office for the Southern District of Alabama. U.S. Attorney's Office for the Southern District of Alabama/Handout via REUTERS

(Reuters) - Health insurer Anthem Inc <ANTM.N> filed a lawsuit against Insys Therapeutics Inc <INSY.O> on Wednesday, alleging the drugmaker fraudulently obtained reimbursements for its opioid painkiller Subsys.

The lawsuit alleges that Insys had paid kickbacks to doctors and lied to Anthem about patients' diagnoses for reimbursements, which would otherwise have not been covered. The lawsuit was filed in federal court in Arizona.

Two former Insys sales representatives, including the wife of its ex-chief executive pleaded guilty on Tuesday to engaging in schemes to pay kickbacks to medical practitioners to prescribe Subsys.

A box of the Fentanyl-based drug Subsys, made by Insys Therapeutics Inc, is seen in an undated photograph provided by the U.S. Attorney's Office for the Southern District of Alabama. U.S. Attorney's Office for the Southern District of Alabama/Handout via REUTERS

The pleas came amid ongoing investigations of Insys related to Subsys, an under-the-tongue spray intended for cancer patients that contains fentanyl, a highly addictive and regulated synthetic opioid.

Federal prosecutors in Boston in December announced charges against six former Insys executives and managers in connection with the probes.

(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Anil D'Silva)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.